Goshuyuto, rabeprazole shown to treat refractory H. pylori

<i>Goshuyuto</i>, rabeprazole shown to treat refractory <i>H. pylori</i>

(HealthDay)—Refractory Helicobacter pylori (HP) infection can be successfully treated with goshuyuto and rabeprazole, according to a case report published online Aug. 28 in the Journal of Digestive Diseases.

Yutaka Nagata, M.D., Ph.D., from Suwa Central Hospital in Nagano, Japan, and colleagues describe three cases of refractory HP infection after vonoprazan-based triple therapy.

All the had HP infection with , and were treated with eradication therapy, according to the researchers. The patients' urea breath tests were positive after primary triplet therapy with amoxicillin, clarithromycin, and rabeprazole (case 1) or vonoprazan (case 2, 3). Their urea breath tests were still positive after subsequently receiving secondary eradication therapy with amoxicillin, metronidazole, and vonoprazan (case 1, 2) or rabeprazole (case 3). Their urea breath test became negative after Kampo eradication therapy consisting of goshuyuto 2.5 g three-times daily plus rabeprazole 10 mg twice daily for two days.

"Goshuyuto treatment is worth trying as another therapeutic option," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

Citation: Goshuyuto, rabeprazole shown to treat refractory H. pylori (2017, September 5) retrieved 10 May 2024 from https://medicalxpress.com/news/2017-09-goshuyuto-rabeprazole-shown-refractory-ih.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Vonoprazan-based triple tx feasible for H. pylori

0 shares

Feedback to editors